Moderna’s vaccine is being studied in combination with Merck’s Keytruda to treat patients with high-risk melanoma, the deadliest form skin cancer.
Moderna and Merck will jointly develop a cancer vaccine for high-risk melanoma patients
Share This Story, Choose Your Platform!
About the Author: David Hilbern
